Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT - Get Free Report) shares rose 1% during trading on Thursday . The stock traded as high as $0.12 and last traded at $0.12. Approximately 42,939 shares changed hands during mid-day trading, a decline of 75% from the average daily volume of 173,214 shares. The stock had previously closed at $0.12.
Provectus Biopharmaceuticals Stock Performance
The firm has a 50 day simple moving average of $0.12 and a two-hundred day simple moving average of $0.11.
Provectus Biopharmaceuticals Company Profile
(
Get Free Report)
Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
Featured Stories
Before you consider Provectus Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Provectus Biopharmaceuticals wasn't on the list.
While Provectus Biopharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
